- Home
- IVVD vs VTVT Comparison
IVVD vs VTVT Comparison
Compare IVVD & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- VTVT
- Stock Information
- Founded
- IVVD 2020
- VTVT 2015
- Country
- IVVD United States
- VTVT United States
- Employees
- IVVD N/A
- VTVT N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- VTVT Health Care
- Exchange
- IVVD Nasdaq
- VTVT Nasdaq
- Market Cap
- IVVD 69.0M
- VTVT 56.7M
- IPO Year
- IVVD 2021
- VTVT 2015
- Fundamental
- Price
- IVVD $0.74
- VTVT $17.85
- Analyst Decision
- IVVD Strong Buy
- VTVT Strong Buy
- Analyst Count
- IVVD 3
- VTVT 2
- Target Price
- IVVD $5.85
- VTVT $35.50
- AVG Volume (30 Days)
- IVVD 1.3M
- VTVT 9.3K
- Earning Date
- IVVD 08-13-2025
- VTVT 08-07-2025
- Dividend Yield
- IVVD N/A
- VTVT N/A
- EPS Growth
- IVVD N/A
- VTVT N/A
- EPS
- IVVD N/A
- VTVT N/A
- Revenue
- IVVD $36,688,000.00
- VTVT $17,000.00
- Revenue This Year
- IVVD $446.60
- VTVT N/A
- Revenue Next Year
- IVVD $112.63
- VTVT N/A
- P/E Ratio
- IVVD N/A
- VTVT N/A
- Revenue Growth
- IVVD N/A
- VTVT N/A
- 52 Week Low
- IVVD $0.35
- VTVT $12.12
- 52 Week High
- IVVD $2.74
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- IVVD 48.03
- VTVT 59.11
- Support Level
- IVVD $0.70
- VTVT $14.83
- Resistance Level
- IVVD $0.77
- VTVT $15.16
- Average True Range (ATR)
- IVVD 0.05
- VTVT 0.77
- MACD
- IVVD -0.00
- VTVT 0.33
- Stochastic Oscillator
- IVVD 45.94
- VTVT 91.21
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.